Scinai Reports Q1 Results, Completes Strategic CDMO Acquisition with $6.2M Bargain Gain
SCNI is trading near its 52-week low of $0.3 (12% above the low) on light trading volume (0.4× avg).
Summary
Scinai reported Q1 2026 results, turning a profit due to a $6.2 million non-cash gain from completing the Recipharm Israel acquisition, which also boosted cash and expanded its CDMO business.
Key Events · Earnings and Guidance · SCNI
-
Q1 2026 Financial Results
Reported a net income of $3.6 million, a significant improvement from a $1.6 million loss in Q1 2025, primarily due to a $6.2 million non-cash bargain purchase gain from the Recipharm Israel acquisition. Operating loss, however, widened to $2.5 million from $1.6 million year-over-year.
-
Strategic CDMO Acquisition Completed
Finalized the acquisition of Recipharm Israel, expanding its contract development and manufacturing organization (CDMO) platform. The acquisition added approximately $2.8 million in cash and $3.6 million in manufacturing infrastructure and equipment.
-
Cash Position Improved
Cash, cash equivalents, and restricted cash increased to $3.1 million as of March 31, 2026, up from $1.8 million at the end of 2025, bolstered by the acquired cash.
-
Non-Dilutive Funding Progress
Advanced multiple grant applications in Poland and Israel to support its therapeutic pipeline and CDMO expansion, with several decisions expected in the second half of 2026.
Analysis · SCNI · Life Sciences
Scinai Immunotherapeutics reported Q1 2026 financial results, showing a net profit driven by a significant non-cash bargain purchase gain from the completed acquisition of Recipharm Israel. This acquisition materially expanded the company's CDMO platform, adding $2.8 million in cash and $3.6 million in manufacturing infrastructure, which is critical for a company facing going concern doubts and Nasdaq delisting threats. While operating losses widened, progress on non-dilutive grant funding initiatives offers a potential lifeline for future development programs.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNI was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.30 to $3.48. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.